Combination therapy for advanced HR-positive, HER2-low breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a new combination of two targeted medicines for people with a certain type of advanced breast cancer that has grown despite hormone therapy. The medicines may help shrink tumors and slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your breast cancer is metastatic (spread to other parts of the body).
- Your tumor is HER2-low or HER2-ultralow, which means it has very little of the HER2 protein.
- Your tumor is hormone receptor positive (HR+), meaning it responds to hormones like estrogen.
- You have had a significant progression after endocrine therapy: either within 6 months of starting your first-line endocrine therapy, or after two or more prior lines of endocrine therapy.
- You have at least one measurable tumor that can be seen on scans.
- You do not have serious heart, lung, or brain conditions that would make the trial risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two study drugs (JSKN016 and D-0502) for people with a common type of advanced breast cancer (HR-positive, HER2-negative) that has grown after standard hormonal and CDK4/6 inhibitor treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This study tests a new treatment for advanced HER2-negative breast cancer. Doctors will take immune cells from lymph nodes near your tumor, grow them in a lab, and then give them back to you along with chemotherapy and immunotherapy. This approach aims to help your body fight the cancer more effectively.
This trial tests a new drug called SSGJ-612 for people with advanced solid tumors that have stopped responding to standard treatments. It is specifically for patients whose tumors have a protein called HER2, and it aims to see if the drug can shrink or control the cancer.
This trial tests two new antibody drugs (SSGJ-705 and SSGJ-612), alone or combined with chemotherapy, in patients with advanced cancers that have a protein called HER2. The study aims to see if this combination can shrink tumors and help patients live longer.
This trial tests a new drug called SSGJ-705, given alone or with other treatments, for advanced cancers that have a specific protein (HER2) on their surface. It is for people with lung, breast, or stomach cancer that has spread and hasn't gotten better with other treatments.
This study tests whether combining two new drugs (AK146D1 and AK112) can help people with advanced breast cancer that is HER2-negative (a type that doesn't have too much of a specific growth protein). The goal is to see if this combination can shrink tumors and improve survival.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.